AcLys-PABC-VC-Aur0101

• UNSPSC Description:

  AcLys-PABC-VC-Aur0101 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AcLys-PABC-VC-Aur0101.html

• Purity:

  98.49

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(NC(C)(C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N2[C@H]([C@@H]([C@H](C(N[C@@H](CC3=CC=CC=C3)C4=NC=CS4)=O)C)OC)CCC2)=O)=O)=O)=O)C=C1)=O)=O)=O)=O

• Molecular Weight:

  1318.67

• References & Citations:

  [1]Costa MJ, et al. Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019 Feb 21;9(1):2443.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Clinical Information:

  No Development Reported

• CAS Number:

  1438851-17-2